Search the Newsreel

Janus Henderson Group (ACHV) reports 5,502,064 Achieve Life shares under management

Janus Henderson Group Ltd., through its affiliated asset managers, has disclosed beneficial ownership of 5,502,064 shares of Achieve Life Sciences, Inc. (ACHV) common stock, representing 5.4% of the outstanding shares. These shares include those obtainable via warrants and are held in various Managed Portfolios, …

Achieve Life Sciences, Inc. Stock 12‑Month Price Target Cut to $13.83, Implies 107% Upside

Achieve Life Sciences, Inc.'s average 12-month price target has been lowered slightly from $13.91 to $13.83 by 12 analysts, with predictions ranging from $9 to $21 per share. This new target suggests a potential upside of approximately 107% from its closing price on August …

Achieve stock gains Overweight at Morgan Stanley (ACHV:NASDAQ)

Morgan Stanley initiated coverage on Achieve Life Sciences (ACHV) with an Overweight rating and a $13 price target. The positive outlook is based on the company's anti-smoking agent, cytisinicline. Following this news, ACHV stock traded higher in premarket activity.

HC Wainwright Has Optimistic Outlook of ACHV Q3 Earnings

Morgan Stanley initiates Achieve Life Sciences stock at overweight

Morgan Stanley has initiated coverage on Achieve Life Sciences (NASDAQ: ACHV) with an overweight rating and a price target of $13.00, indicating significant upside potential from its current trading price of $6.69. The company is developing cytisinicline for nicotine addiction, which has shown promising …

Achieve Life Sciences Stock Has Nearly Tripled in the Last Year. Now It Just Needs to Turn a Profit.

Research Analysts Set Expectations for ACHV FY2028 Earnings

ACHIEVE LIFE SCIENCES, INC. 6M 2026: Net loss $(84.9)M, EPS $(1.15) — 10-Q Summary

ACHIEVE LIFE SCIENCES, INC. reported a consolidated net loss of $(84.9)M for the six months ended June 30, 2026, an increase from a $(25.5)M loss in the prior year. The diluted loss per share was $(1.15) for the same period, compared to $(0.74) in …

Achieve Life Sciences (NASDAQ: ACHV) posts larger Q2 2026 loss but secures $354M financing

Achieve Life Sciences reported a larger Q2 2026 net loss of $74.8 million but secured up to $354 million in financing, including $180 million upfront. The company received an FDA Complete Response Letter for its cytisinicline NDA due to manufacturing and labeling issues, not …

Achieve Life Sciences (NASDAQ:ACHV) Posts Earnings Results, Misses Expectations By $0.12 EPS

Achieve Life Sciences (NASDAQ:ACHV) reported quarterly earnings of $(0.28) per share, falling short of analysts' consensus estimates by $0.12. Despite missing earnings expectations, ACHV shares saw a slight increase of 0.7% to $6.71, and institutional investors collectively own a significant portion of the company. …

Achieve Life Sciences (ACHV) Advances Cytisinicline Commercialization Amid Mixed Valuation Signals

Achieve Life Sciences GAAP EPS of -$0.80 misses by $0.64

* Achieve Life Sciences press release [https://seekingalpha.com/pr/20614674-achieve-life-sciences-reports-second-quarter-2026-financial-results-and-provides-business] (ACHV [https://seekingalpha.com/symbol/ACHV]): Q2 GAAP EPS of -$0.80 misses by $0.64. * As of June 30, 2026, the Company’s cash, cash equivalents, and marketable securities were $187.3 million. MORE ON ACHIEVE LIFE SCIENCES * Achieve Life Sciences: Despite …

Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

Achieve Life Sciences announced its second-quarter 2026 financial results, highlighted by closing a private placement of up to $354 million. The company received a Complete Response Letter from the FDA for cytisinicline's NDA due to cGMP issues and incomplete labeling, but no deficiencies in …

Achieve Life Sciences (ACHV) Earnings Date and Reports 2026

Achieve Life Sciences (NASDAQ:ACHV) Stock Price Passes Above Two Hundred Day Moving Average - What's Next?

Achieve Life Sciences (NASDAQ:ACHV) stock price recently crossed above its 200-day moving average, trading as high as $6.80 and closing at $6.67, significantly above the $4.88 average. Analysts maintain a "Buy" consensus with a $16 price target, citing the company's Q2 EPS beat and …

Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT) and Achieve Life Sciences (ACHV)

William Blair analyst Brandon Vazquez downgraded PROCEPT BioRobotics (PRCT) to Hold, citing a $23.13 average price target with a 15.4% upside. In contrast, LifeSci Capital analyst Patrick Dolezal rated Achieve Life Sciences (ACHV) as a Buy with a $17.00 price target. The article provides …

Achieve Life Sciences Appoints Ronald Dadino and Gloria Cosgrove to Lead CMC, Supply Chain, and Quality

Achieve Life Sciences has appointed Ronald Dadino as Senior Vice President, Chemistry, Manufacturing and Controls (CMC) and Supply Chain, and Gloria Cosgrove as Senior Vice President, Quality. These appointments aim to strengthen the company's manufacturing, supply chain, and quality functions as it prepares for …

EX-99.1

Achieve Life Sciences announced a private placement aiming to raise up to $354 million, with an initial $180 million funding and an additional $174 million from warrants tied to FDA approval. This financing, led by several prominent healthcare investors, will support a Phase 3 …

Achieve Life Sciences Announced Granting of New Hire Inducement Awards

Achieve Life Sciences, Inc. has announced the granting of stock options and restricted stock unit (RSU) awards to six new employees under its 2024 Equity Inducement Plan. These awards, totaling 1,190,000 shares for stock options and 125,000 shares for RSUs, are part of the …

Six New Employees Receive Achieve Stock Awards Over Four Years

Achieve Life Sciences announced new-hire equity inducement awards for six employees, comprising stock options for 1,190,000 shares and RSU awards for 125,000 shares. These awards, granted under the 2024 Equity Inducement Plan, are intended to attract and retain talent in accordance with Nasdaq Listing …

Achieve Life Sciences (ACHV) Expected to Post Earnings on Thursday

Achieve Life Sciences (NASDAQ: ACHV) is scheduled to release its Q2 2026 earnings before market open on Thursday, August 6th, with analysts expecting a loss of ($0.18) per share. The company previously beat consensus estimates in May by reporting ($0.19) EPS against a ($0.30) …

Form 4 Achieve Life Sciences Inc For: 29 July By Investing.com

This article reports on a Form 4 filing for Achieve Life Sciences Inc. on July 29, 2026. Form 4 filings are regulatory documents that disclose changes in ownership of company stock by insiders. The article provides the title of the filing and indicates it …

Director awards at Achieve Life Sciences (NASDAQ: ACHV) include options, RSUs

Achieve Life Sciences director Reid Alexander Waldman received equity compensation on July 27, 2026, comprising 25,000 stock options with an exercise price of $6.18 per share and 16,700 Restricted Stock Units (RSUs). Both awards are set to vest 100% on the earlier of July …

ACHV|Achieve Life Sciences Inc|Price:6.185|Chg%:+0.085

This article provides a comprehensive stock analysis of Achieve Life Sciences Inc. (ACHV), highlighting its strong fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. The company, which is focused on developing cytisinicline for smoking and vaping cessation, has …

BlackRock, Inc. (ACHV) discloses 5.1% beneficial stake in Achieve Life Sciences

BlackRock, Inc. has disclosed a beneficial ownership of 5.1% in Achieve Life Sciences, holding 5,271,391 shares of common stock as of June 30, 2026. The firm maintains sole voting power over 5,188,710 shares and sole dispositive power over all 5,271,391 shares. This stake is …

Achieve Life Sciences Inc (ACHV) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Achieve Life Sciences Inc (ACHV)'s dividend and stock split history. It states that ACHV has distributed $0.00 in dividends over the past five years and details a 20-for-1 merger stock split on July 30, 2020. The company's current …

Achieve Life Sciences, Inc. Revenue Breakdown – SWB:SP4P

This article provides a revenue breakdown for Achieve Life Sciences, Inc. (SWB:SP4P) listed on the Stuttgart Stock Exchange. It notes that market data is provided by ICE Data Services and FactSet, and SEC filings by Quartr. The content appears to be a stub or …

Achieve Life Sciences Inc (ACHV) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Achieve Life Sciences Inc (ACHV), detailing its price momentum, support and resistance levels, and the status of various technical indicators and moving averages. ACHV's stock price currently trades between a resistance of $6.91 and a support of …

ACHV: FDA Resubmission And Potential First New Cessation Therapy Could Reignite Upside

Achieve Life Sciences (ACHV) is poised for potential upside due to the upcoming resubmission of its cytisinicline NDA to the FDA, which could result in the first new smoking cessation therapy approval in approximately two decades. Although the fair value estimate has decreased from …

Achieve Life Sciences (ACHV) Q1 2026 earnings summary

Achieve Life Sciences (ACHV) reported its Q1 2026 earnings, detailing strategic leadership changes and a significant private placement raising $180 million initially for the development and commercialization of cytisinicline. The company aims to address unmet needs in nicotine dependence, with cytisinicline accepted by the …

Achieve Life Sciences (ACHV) Registration filing Summary

Achieve Life Sciences (ACHV) has released a registration filing summary detailing its status as a late-stage clinical specialty pharmaceutical company focused on cytisinicline for nicotine dependence. The company recently completed a private placement, raising approximately $180 million, with potential for an additional $173.8 million …

Achieve Life Sciences (ACHV) Corporate presentation Summary

Achieve Life Sciences (ACHV) presented a summary of its corporate activities, highlighting the significant market opportunity for its nicotine dependence treatment, cytisinicline. The presentation detailed the drug's strong clinical efficacy in Phase 3 trials for both smoking and vaping cessation, its favorable tolerability profile, …